Become Affiliate

PepFlow

Download

The Pulse Signal

CJC-1295 (no DAC)

A short-acting Modified GRF 1-29-style GHRH analog that lacks the DAC albumin-binding tail, best understood as a pulse-oriented GH-axis signal rather than the long-acting CJC-1295 form.

GH pulseBody compositionSleepRecovery
TierB
EvidenceEmerging
SafetyLimited Data
FDA statusNot Approved
Last reviewed August 11, 2026 22 citations How to read these labels

What is CJC-1295 (no DAC)?

CJC-1295 without DAC is the common wellness-market name for Modified GRF 1-29, a modified version of the active 1-29 region of growth-hormone-releasing hormone. The practical identity point is simple: it is a GHRH analog, not growth hormone itself.[1][2]

The no-DAC distinction matters because the molecule does not carry the albumin-binding tail. CJC-1295 was engineered to stay in circulation much longer through albumin binding; no-DAC Modified GRF 1-29 is discussed as the shorter-acting, pulse-oriented member of the same GHRH-analog family.[7][8][18]

The biological idea is upstream signaling. GHRH fragments and D-Ala2 analogs can stimulate pituitary GH release in normal men, and older GHRH(1-29) studies show GH and IGF-1 movement after repeated subcutaneous dosing.[1][3][2]

The naming needs precision. CJC-1295, CJC-1295 without DAC, sermorelin, tesamorelin, and CJC-1295 plus ipamorelin blends are related GH-axis topics, but they do not share the same duration, dosing logic, evidence package, or safety review.[18][7][5] For more context, read the CJC-1295 DAC and no-DAC comparison.

What CJC-1295 (no DAC) is investigated for

CJC-1295 (no DAC) evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

GH pulse and IGF-1 biomarker support

Injectable

50%Emerging

This is the strongest no-DAC claim: short-acting GHRH-fragment evidence supports GH-axis signaling, while direct no-DAC outcome evidence remains limited.[1][2][3]

Human evidence

Human GHRH(1-29) and D-Ala2 analog studies show pituitary GH response, lower metabolic clearance for the D-Ala2 analog, and repeated-dose GH/IGF-1 movement in older men. That supports the short-acting GHRH-fragment rationale but is not a dedicated no-DAC CJC-1295 clinical program.[1][2][3]

Animal / mechanistic evidence

The CJC-1295 comparator literature shows how albumin binding creates a different long-acting exposure profile. That contrast is the main mechanistic reason to separate no-DAC Modified GRF 1-29 from albumin-binding CJC-1295.[7][8]

Lean-mass and fat-loss outcomes

Injectable

45%Preliminary

Lean-mass and fat-loss improvement is commonly discussed for no-DAC CJC-1295, but it should read as an indirect GH-axis hypothesis rather than a proven result.[4][14]

Human evidence

Older human GHRH(1-29) studies measured GH/IGF-1, strength, DEXA, and metabolic variables, but they do not establish no-DAC CJC-1295 as a lean-mass or fat-loss treatment. Direct no-DAC fat-loss, lean-mass, or waist-outcome trials are missing.[3][4]

Animal / mechanistic evidence

The rationale comes from GH/IGF-1 biology and GHRH-axis signaling, not from no-DAC animal models showing lean-mass or fat-loss improvements in healthy adults.[7][10]

Sleep quality

Injectable

18%Insufficient

Sleep quality is a common no-DAC CJC-1295 tracking claim, but the evidence supports GH-axis timing physiology more than sleep endpoints.[4]

Human evidence

Nightly GHRH(1-29) studies measured nocturnal GH physiology, and bedtime timing is common in GH-oriented schedules. Those studies do not prove no-DAC CJC-1295 improves sleep quality, sleep stages, or insomnia symptoms.[4][3]

Animal / mechanistic evidence

The mechanism is timing and GH physiology rather than a direct sleep pathway. Evidence should not turn overnight GH rhythm into a sleep-quality claim without sleep endpoints.[9]

Recovery support

Injectable

16%Insufficient

Recovery support is commonly discussed with no-DAC CJC-1295, but it should be shown as an indirect GH-axis claim until recovery-specific human evidence exists.[14][15]

Human evidence

Controlled no-DAC CJC-1295 human evidence does not show faster exercise recovery, injury recovery, soreness reduction, strength gain, or training adaptation. Sports-medicine reviews keep unapproved peptide performance claims separate from proven outcomes.[14][15][16]

Animal / mechanistic evidence

Mechanistic support is limited to GH-axis plausibility and GHRH analog pharmacology. It does not replace recovery-specific human endpoints.[1][2]

Evidence snapshot

50%

Human evidence

Emerging

Human evidence supports GHRH(1-29) and D-Ala2 analog GH signaling, plus older repeated-dose GHRH(1-29) biomarker movement. Dedicated no-DAC CJC-1295 outcome trials are not established.[1][2][3]

40%

Animal / preclinical

Limited

Preclinical and analytical support mainly clarifies the GHRH-analog family and the DAC distinction. The no-DAC page should not borrow DAC mouse or rat outcomes as human no-DAC benefits.[7][13][12]

60%

Mechanism support

Moderate

Mechanism support is stronger than outcome support: no-DAC Modified GRF 1-29 is a GHRH-fragment analog, D-Ala2 modification reduces clearance, and the lack of DAC separates it from albumin-binding CJC-1295.[1][2][7]

Forms & administration

CJC-1295 no DAC is primarily discussed as a subcutaneous, short-acting GHRH analog. Route, DAC status, timing, product identity, and whether it is paired with a GHRP change how the schedule should be interpreted.[3][2]

Injectable

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common injectable protocols use 100-200 mcg per dose.

Frequency

Usually taken 1-3 times daily.[2]

Timing Considerations

Common timing is morning, after a workout, or before bed.[4]

Cycle Length

Common cycles run 8-12 weeks.

What to expect

Same day

Upstream GH-axis pulse, with practical notes around appetite, sleep timing, warmth or flushing, and recovery feel against normal baseline.[1][2][17]

First 1-2 weeks

Early GH and IGF-1 biomarker movement in responsive older men, alongside sleep quality, recovery feel, appetite, water retention, and day-to-day training tolerance.[3]

Weeks 4-8

Steadier lab movement, sleep and recovery patterns, body-composition trend, training tolerance, and metabolic measures across the protocol block.[4]

After stopping

Quick fade of the short-acting GH pulse, with slower settling of IGF-1 labs, weight trend, sleep, and training markers.[2][8]

Safety profile

CJC-1295 no DAC should be treated as endocrine-active and route-specific. Human GHRH-fragment studies are small or adjacent, while FDA flags CJC-1295 compounding concerns involving immunogenicity, peptide impurities, API characterization, increased heart rate, systemic vasodilatory reaction, and limited clinical data.[1][17][18]

Common side effects

Cautions

  • Endocrine medical supervision[3]
  • Unapproved product quality[17][18]
  • Prohibited in sport

What we don't know

Decision-changing unknowns include long-term safety, no-DAC versus DAC risk differences, combination-level safety with GHRPs, repeated non-study use, product identity, special-population safety, and whether downstream outcomes justify endocrine exposure.[17][18][14]

Who CJC-1295 (no DAC) is not for

Route-specific avoid and medical-review notes:

  • Competitive athletes

    Competitive athletes should avoid CJC-1295 no DAC unless their anti-doping authority provides route-specific written clearance. WADA prohibits GHRH and analogs including CJC-1295.

  • Endocrine disease or glucose dysregulation

    Medical review is needed in endocrine disease, diabetes, insulin resistance, or abnormal GH/IGF-1-related labs because no-DAC CJC-1295 acts through the GH/IGF-1 axis.[3]

  • Cancer or growth-factor-sensitive conditions

    This is a medical-review caution rather than a documented no-DAC cancer-outcome finding. GH/IGF-1 biomarker movement should not be handled through self-directed use in growth-factor-sensitive histories.[3][17]

  • Pregnancy, breastfeeding, or pediatric use

    Pregnancy, breastfeeding, and pediatric use are not supported by route-specific no-DAC CJC-1295 safety data.[17][18]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Other GH-axis drugs or secretagogues

    This is a theoretical additive-exposure caution. Combining no-DAC CJC-1295 with GH, GHRPs, ipamorelin, CJC-1295, sermorelin, tesamorelin, or other GH-axis agents can make GH/IGF-1 exposure and side-effect interpretation harder to manage.[3][17]

  • Glucose-active medications

    This is a theoretical endocrine-monitoring caution. GH/IGF-1 signaling intersects with metabolic regulation, so insulin, diabetes drugs, or weight-management medications need clinician review.[3]

Pairing notes

Commonly included in these stacks

Not recommended with

Somatropin: compounded GH/IGF-1 effectsInjectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[1][17][20]

CJC-1295: overlapping GHRH signalingInjectable

CJC variants provide different exposure profiles but stimulate the same GHRH receptor pathway. Combining them duplicates GH/IGF-1 stimulation and makes exposure and monitoring harder to interpret.[8][2][18]

Sermorelin: overlapping GHRH signalingInjectable

Sermorelin and CJC-1295 No DAC are closely related GHRH-receptor approaches. Using both duplicates growth-hormone release signaling without a validated combined regimen.[21][1][22]

Related peptides

How it works

The starting point is natural GHRH. The active 1-29 region can stimulate pituitary somatotroph cells to release GH, and human bolus data show both native GHRH(1-29)-NH2 and a D-Ala2 analog can produce GH responses.[1]

The D-Ala2 modification helps explain why Modified GRF 1-29 exists as a research-market concept. In normal men, D-Ala2 GHRH(1-29) showed lower metabolic clearance and a longer disappearance half-time than native GHRH(1-29)-NH2.[2]

The no-DAC form lacks the albumin-binding extension that defines CJC-1295. The long-acting form was designed around albumin binding and multi-day exposure, so it should not be used as a drop-in schedule model for no-DAC Modified GRF 1-29.[7][8][18]

The translation limit is downstream outcomes. A GH pulse and IGF-1 movement can be biologically meaningful, but they do not automatically prove better sleep, faster recovery, fat loss, muscle gain, cognition, or vitality.[4][5][14]

Research gaps & open questions

What the current literature has not yet settled about CJC-1295 (no DAC):

01

Trials in people need to study the no-DAC form itself. Evidence from related growth-hormone-releasing compounds or the longer-acting DAC form cannot establish its effects.[2][3][8]

02

Controlled trials still need to show whether the no-DAC form actually improves fat loss, lean mass, sleep, recovery, training response, or day-to-day wellbeing.[14][15]

03

Direct comparisons between no-DAC and DAC forms should test whether their different duration and growth-hormone-release patterns lead to different benefits or long-term risks.[8][18]

04

CJC-1295 no DAC and ipamorelin or other growth-hormone-releasing peptides need to be studied as combinations, including dose, monitoring, side effects, and anti-doping risk.

Common questions

What is the difference between CJC-1295 and no DAC?

CJC-1295 has an albumin-binding extension designed for long duration. No-DAC CJC-1295 is usually Modified GRF 1-29, a shorter-acting GHRH analog used around pulse timing rather than multi-day exposure.[7][8][18]

What is CJC-1295 no DAC investigated for?

It is mainly discussed for GH pulse and IGF-1 biomarker support, body-composition improvements, sleep quality, and recovery support. The strongest support is GH-axis signaling; the downstream results remain weak.[1][3][4]

What is the CJC-1295 no DAC dose?

Common Modified GRF 1-29 protocols usually use 100-200 mcg per dose, 1-3 times daily, with morning, post-workout, or before-bed timing.

Can CJC-1295 no DAC be combined with ipamorelin?

No-DAC CJC-1295 and ipamorelin are a common GH-axis stack candidate because they act through different signaling pathways. Combination-level efficacy, safety, dosing, monitoring, and sports status still need separate review before the pair is treated as recommended.[14]

Is CJC-1295 no DAC allowed in sport?

No for WADA-governed sport. WADA prohibits growth hormone releasing factors, including GHRH analogs such as CJC-1295, at all times.[12]

Myths & misconceptions

Myth

No-DAC CJC-1295 is just faster CJC-1295.

Reality

They should be treated as different pharmacology problems. DAC adds albumin-binding chemistry and multi-day exposure; no-DAC Modified GRF 1-29 lacks that extension and is scheduled around short pulses.[7][8][18]

Myth

Pulse-oriented dosing proves no-DAC is safer.

Reality

Shorter exposure may change the risk profile, but it does not prove long-term safety. Both forms act through GH/IGF-1 biology, and CJC-1295-related products still carry product-quality and endocrine-monitoring concerns.[17][3]

Myth

CJC-1295 no DAC plus ipamorelin is a proven recovery stack.

Reality

The pair is common and mechanistically coherent, but combination-level outcome, safety, dose, timing, and anti-doping evidence need their own review.[14]

History & discovery

No-DAC CJC-1295 sits at the intersection of older GHRH(1-29) pharmacology, D-Ala2 analog work, and later CJC-1295 development. Its public use pattern grew from a naming shortcut for Modified GRF 1-29, not from a dedicated no-DAC approval program.[1][2][7][18]

A human study found GHRH(1-29)-NH2 and a D-Ala2 analog stimulated GH release in normal men, with the D-Ala2 analog showing greater potency.[1]

Older-men studies examined repeated GHRH(1-29) dosing, while a D-Ala2 GHRH(1-29) pharmacokinetic study found lower clearance than native GHRH(1-29).[3][2]

CJC-1295 was identified as a long-lasting albumin-binding GHRH analog and then studied in healthy adults for multi-day GH and IGF-1 biomarker response.[7][8]

Analytical and sports-medicine literature discusses modified GRF and GHRH analogs in doping and unapproved peptide settings, while FDA materials continue to distinguish CJC-1295-related forms for compounding review.[11][12][18]

Published research22 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Stay on track with your long-term goals.

Use PepFlow to record your CJC-1295 (no DAC) protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00